PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Company ReportsEndoceutics
Endoceutics
Download report
Favorite
Financial
Marketed Drugs
Clinical Trials
Financial
Stock price
No data
Company Revenue
No data
Revenue by Drug
Loading
Marketed Drugs
Therapeutic Areas:
All
Classification:
All
Include Generics:
Trade Name
Drug Name
Approved
Patent Expires
Indication
IntrarosaPrasterone2018-01-082028-2031
Adrenal insufficiency
,
Dyspareunia
,
Postmenopause
,
Sexual and gender disorders
,
Lupus vulgaris
Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Drug Name
Phase 1
Phase 2
Phase 3
Phase 4
Indication
Prasterone
atrophy
,
atrophic vaginitis
,
hypokinesia
,
psychological sexual dysfunctions
,
breast neoplasms
,
flushing
,
hot flashes
,
dyspareunia
,
syndrome
,
menopause
Nepidermin
ulcerative colitis
,
colitis
,
ulcer
Gl701
type 1 diabetes mellitus
,
menstruation disturbances
,
pharmacokinetics
,
drug-related side effects and adverse reactions
,
metabolic side effects of drugs and substances
,
sarcoma
,
synovial sarcoma
,
pure autonomic failure
,
hypoglycemia
,
neoplasms
,
rheumatoid arthritis
,
arthritis
,
male breast neoplasms
,
pulmonary arterial hypertension
,
post-traumatic stress disorders
,
substance withdrawal syndrome
,
libido
,
erectile dysfunction
,
crohn disease
,
hiv infections
,
multiple myeloma
,
plasma cell neoplasms
,
plasmacytoma
,
xerostomia
,
lacrimal apparatus diseases
,
salivary gland diseases
,
mood disorders
,
depressive disorder
,
asthma
,
genotype
,
systemic lupus erythematosus
,
primary ovarian insufficiency
,
premature menopause
,
female infertility
,
hypertension
,
pulmonary hypertension
,
hypokinesia
,
psychological sexual dysfunctions
,
adrenal insufficiency
,
aging
,
postmenopause
,
infections
,
urinary tract infections
,
communicable diseases
,
menopause
,
ovulation induction
,
hot flashes
,
chronic obstructive pulmonary disease
,
obstructive lung diseases
,
malaria
,
recurrence
,
ovarian hyperstimulation syndrome
,
flushing
,
female genital neoplasms
,
premature birth
,
anorexia
,
anorexia nervosa
,
sexual and gender disorders
,
skin aging
,
myotonic dystrophy
,
addison disease
,
infertility
,
atrophy
,
breast neoplasms
,
atrophic vaginitis
,
syndrome
,
dyspareunia
,
sjogren's syndrome
,
osteoporosis
,
contraception behavior
,
blood coagulation
,
frailty
,
fatigue
,
polycystic ovary syndrome
,
obesity
,
insulin resistance
,
covid-19
,
multiple sclerosis
,
sclerosis
,
hyperandrogenism
,
endocrine system diseases
,
brain neoplasms
,
central nervous system neoplasms
,
nervous system neoplasms
,
acne vulgaris
,
severe acute respiratory syndrome
,
professional burnout
,
psychological burnout
,
caregiver burden
,
chronic pain
,
psychological stress
,
physiological stress
,
postmenopausal osteoporosis
,
inflammation
,
healthy volunteers/patients
,
cardiovascular diseases
,
coronary disease
,
heart diseases
,
adrenocortical adenoma
,
cushing syndrome
,
adrenal gland neoplasms
,
adrenocortical hyperfunction
,
diabetes mellitus
,
oligomenorrhea
,
hirsutism
,
skin diseases
,
epidermolysis bullosa simplex
,
epidermolysis bullosa
,
disorders of sex development
,
epidermolysis bullosa dystrophica
,
junctional epidermolysis bullosa
,
turner syndrome
,
gonadal dysgenesis
,
dietary supplements
,
autistic disorder
,
autism spectrum disorder
,
pervasive child development disorders
,
post-acute covid-19 syndrome
,
physiological sexual dysfunction
,
body image
,
candidiasis
,
lichen planus
,
vulvodynia
,
endometriosis
,
ureaplasma infections
,
bacterial vaginosis
,
vaginitis
,
lichen sclerosus et atrophicus
,
overweight
,
thinness
,
urinary calculi
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use